GlassScriptPhysician profile
Benjamin F Thompson
NPI 1710996079
$5,912.85
in general payments reported to CMS, 2019-2025
30 companies · $26.88 in 2025
The $26.88 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $768 · 2021: $1,338 · 2022: $1,527 · 2023: $341 · 2025: $26.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,595.43 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $660.42 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.44 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Csl Behring | $378.76 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $340.51 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $263.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $261.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $222.60 | 2019-2022 | |
| Philips North America LLC | $205.50 | 2019-2023 | |
| Genzyme Corporation | $195.98 | 2020-2023 | |
| Actelion Pharmaceuticals US, INC. | $169.77 | 2019-2021 | |
| Baxter Healthcare | $148.16 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Abiomed | $121.97 | 2021 | |
| Mylan Specialty L.P. | $102.81 | 2019-2022 | |
| Genentech USA, INC. | $100.98 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $94.96 | 2019 | |
| United Therapeutics Corporation | $89.43 | 2019-2022 | |
| Insmed, INC. | $83.61 | 2020-2022 | |
| Grifols USA, LLC | $80.02 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Intuitive Surgical, INC. | $73.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.52 | 2021-2022 | |
| Amgen INC. | $38.97 | 2023 | Tezspire |
| Gilead Sciences, INC. | $36.08 | 2019 | |
| Hologic Sales and Service, LLC | $26.88 | 2025 | Novasure, Myosure Tissue Removal Device |
| Teva Pharmaceuticals USA, INC. | $24.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $16.11 | 2022 | |
| Haemonetics Corporation | $12.90 | 2023 | |
| Boston Scientific Corporation | $12.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.